Literature DB >> 27977915

Transient and stable CHO expression, purification and characterization of novel hetero-dimeric bispecific IgG antibodies.

Yashas Rajendra1, Robert B Peery1, Maria D Hougland1, Gavin C Barnard1, Xiufeng Wu2, Jonathan R Fitchett2, Michael Bacica2, Stephen J Demarest2.   

Abstract

IgG bispecific antibodies (BsAbs) represent one of the preferred formats for bispecific antibody therapeutics due to their native-like IgG properties and their monovalent binding to each target. Most reported studies utilized transient expression in HEK293 cells to produce BsAbs. However, the expression of biotherapeutic molecules using stable CHO cell lines is commonly used for biopharmaceutical manufacturing. Unfortunately, limited information is available in the scientific literature on the expression of BsAbs in CHO cell lines. In this study we describe an alternative approach to express the multiple components of IgG BsAbs using a single plasmid vector (quad vector). This single plasmid vector contains both heavy chain genes and both light chain genes required for the expression and assembly of the IgG BsAb, along with a selectable marker. We expressed, purified, and characterized four different IgG BsAbs or "hetero-mAbs" using transient CHO expression and stable CHO minipools. Transient CHO titers ranged from 90 to 160 mg/L. Stable CHO titers ranged from 0.4 to 2.3 g/L. Following a simple Protein A purification step, the percentage of correctly paired BsAbs ranged from 74% to 98% as determined by mass spectrometry. We also found that information generated from transient CHO expression was similar to information generated using stable CHO minipools. In conclusion, the quad vector approach represents a simple, but effective, alternative approach for the generation of IgG BsAbs in both transient CHO and stable CHO expression systems.
© 2017 American Institute of Chemical Engineers Biotechnol. Prog., 33:469-477, 2017. © 2017 American Institute of Chemical Engineers.

Entities:  

Keywords:  CHO; Chinese hamster ovary; bispecific antibodies; quad vector

Mesh:

Substances:

Year:  2017        PMID: 27977915     DOI: 10.1002/btpr.2414

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  6 in total

Review 1.  Expression of mammalian proteins for diagnostics and therapeutics: a review.

Authors:  Jacqueline Kar Kei Mark; Crystale Siew Ying Lim; Fazlina Nordin; Gee Jun Tye
Journal:  Mol Biol Rep       Date:  2022-06-08       Impact factor: 2.742

2.  Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.

Authors:  K J Froning; A Leaver-Fay; X Wu; S Phan; L Gao; F Huang; A Pustilnik; M Bacica; K Houlihan; Q Chai; J R Fitchett; J Hendle; B Kuhlman; S J Demarest
Journal:  Protein Sci       Date:  2017-07-31       Impact factor: 6.725

Review 3.  Design and Production of Bispecific Antibodies.

Authors:  Qiong Wang; Yiqun Chen; Jaeyoung Park; Xiao Liu; Yifeng Hu; Tiexin Wang; Kevin McFarland; Michael J Betenbaugh
Journal:  Antibodies (Basel)       Date:  2019-08-02

4.  Generalizable design parameters for soluble T cell receptor-based T cell engagers.

Authors:  Karen J Froning; Arlene Sereno; Flora Huang; Stephen J Demarest
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 13.751

5.  Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.

Authors:  Mathilde Poussin; Arlene Sereno; Xiufeng Wu; Flora Huang; Jason Manro; Shanshan Cao; Carmine Carpenito; Andrew Glasebrook; Daniel J Powell; Stephen Demarest
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

6.  Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics.

Authors:  Karen Froning; Jack Maguire; Arlene Sereno; Flora Huang; Shawn Chang; Kenneth Weichert; Anton J Frommelt; Jessica Dong; Xiufeng Wu; Heather Austin; Elaine M Conner; Jonathan R Fitchett; Aik Roy Heng; Deepa Balasubramaniam; Mark T Hilgers; Brian Kuhlman; Stephen J Demarest
Journal:  Nat Commun       Date:  2020-05-11       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.